Latest 10-Q quarterly reports

Dyadic International reported a net loss of $2.12 million for Q2 2026, with significant concerns remaining about its ability to continue as a going concern.

Aprea Therapeutics reports continued net losses and cash burn, with funding expected to last into Q1 2028, while advancing its APR-1051 clinical program.

QHSLab, Inc. filed its Q2 2026 10-Q, showing increased revenues driven by its Integrated Service Program, but continued operating losses and a going concern warning.

flyExclusive, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting a 15.6% increase in revenue to $207.5 million for the first six months, but also highlighting continued net losses and a substantial accumulated deficit.

Avalyn Pharma Inc. details progress in its Phase 2b clinical trial for AP01 and Phase 2 trial for AP02, alongside a robust cash position post-IPO, while acknowledging ongoing development risks.

B&G Foods, Inc. reported a net loss for the period ended July 4, 2026, with a significant decrease in net sales driven by divestitures and base business declines, alongside increased interest expenses.

Century Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in its iPSC cell therapy platform, significant operating losses, and a substantial cash position sufficient into early 2029.

Guerrilla RF, Inc. announced a significant 49% year-over-year revenue increase for the second quarter of fiscal 2026, driven by strong performance in its catalog and infrastructure segments, alongside improved gross margins.

CNS Pharmaceuticals, Inc. filed its Q2 2026 Form 10-Q, detailing financial performance, operational updates, and strategic shifts, including a pivot from glioblastoma multiforme and exploration of out-licensing legacy assets.

LiqTech International Inc. reported a wider net loss for the second quarter of 2026, driven by decreased revenues and increased operating expenses, though a significant capital raise bolstered liquidity.

Xilio Therapeutics files its Q2 2026 Form 10-Q, detailing increased collaboration revenue and ongoing R&D investments, while managing cash runway.

Capstone Holding Corp. has amended its Q3 2025 report to restate prior financial figures related to share counts and net loss per share, while also disclosing material weaknesses in its internal financial reporting controls.

Capstone Holding Corp. has amended its Q2 2025 report to restate weighted average share counts and net loss per share, citing errors in calculation and identifying material weaknesses in internal controls.

Capstone Holding Corp. files an amendment to its Q1 2026 report, restating prior period net loss per share due to an error in calculating weighted average shares, while also disclosing material weaknesses in internal controls and ongoing Nasdaq listing concerns.

Arbutus Biopharma reports a substantial $178.4 million settlement payment from Moderna and positive clinical trial updates for its chronic hepatitis B therapeutic, imdusiran.

Capstone Holding Corp. announced Q2 2026 results, showing increased net sales driven by acquisitions, but continued net losses and ongoing challenges with Nasdaq listing compliance.

SideChannel, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, highlighting a decrease in total revenue and significant going concern risks.

Sutro Biopharma's Q2 2026 filing reveals a substantial revenue decrease driven by the termination of the Ipsen collaboration, alongside continued net losses, though clinical development for STRO-004 shows early promise.

TScan Therapeutics reports continued net losses and substantial doubt about its ability to continue as a going concern, with cash reserves expected to fund operations into Q2 2027.

Cypherpunk Technologies Inc. filed its Q2 2026 10-Q, detailing a shift towards a digital asset treasury strategy alongside its ongoing biopharmaceutical research, marked by a substantial unrealized gain on digital assets but also significant operating losses.

HG Holdings, Inc. announced a significant increase in total revenues for the second quarter of 2026, driven by substantial growth in management fees and title insurance operations.

Protalix BioTherapeutics announces a significant surge in revenue and net income for the second quarter of 2026, driven by strong sales of Elfabrio and Elelyso.

Octave Intelligence plc reported a significant net loss of $1.97 billion for the quarter ended June 30, 2026, driven by substantial goodwill and intangible asset impairments totaling over $2.1 billion.

Lexeo Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing clinical trial progress and financial performance, including a net loss of $25.9 million.

Milestone Pharmaceuticals Inc. reports on the commercial launch of CARDAMYST, progress in its AFib-RVR clinical program, and financial updates for the quarter ended June 30, 2026.

WhiteFiber, Inc. reported increased revenues for Q2 2026, but also a widening net loss and significant increases in operating expenses and debt.

Enanta Pharmaceuticals reported a decrease in Q3 2026 revenue to $14.4 million from $18.3 million in the prior year, driven by lower HCV sales, while continuing to invest heavily in its RSV and immunology drug development programs.

Liquidia Corporation reported a substantial increase in product sales driven by YUTREPIA, alongside significant investments in research and development and ongoing litigation.

Unicycive Therapeutics reported a significant increase in net loss for the six months ended June 30, 2026, alongside a setback in its OLC New Drug Application, though it bolstered its cash position through common stock sales.

Cambridge Acquisition Corp. reports on its financial condition and operational activities for the quarter ended June 30, 2026, highlighting income from trust account investments and ongoing efforts to identify a business combination target.